Residency · Residency · Nuclear Medicine

Radium-223 for Bone-Predominant Metastatic Prostate Cancer

Introduction

Radium-223 dichloride (Xofigo) is an FDA-approved alpha-emitting radiopharmaceutical for the treatment of symptomatic bone metastases in castration-resistant prostate cancer (CRPC) without known visceral metastatic disease. Approved in 2013 based on the ALSYMPCA trial, it was the first alpha-emitter to demonstrate an overall survival benefit in a phase III oncology trial.

Radiopharmaceutical Properties

Ra-223 Physics

Ra-223 is an alkaline earth metal that behaves as a calcium mimetic, naturally targeting areas of increased bone turnover. It is an alpha emitter that produces 4 alpha particles in its decay chain. The alpha particle range is less than 100 micrometers, which corresponds to only 2 to 10 cell diameters. The linear energy transfer is high at approximately 80 keV per micrometer, and the half-life is 11.4 days. The daughter isotopes in the decay chain are Rn-219, Po-215, Pb-211, Bi-211, and Tl-207, all of which are short-lived.

Mechanism of Action

Ra-223 preferentially incorporates into osteoblastic bone metastases at sites of new bone formation, where it delivers highly cytotoxic alpha radiation to tumor cells in close proximity to bone surfaces. The short alpha range results in minimal bystander damage to surrounding normal tissue. Double-strand DNA breaks are the primary mechanism of cell killing. Alpha particles are less susceptible to radioresistance mechanisms compared to beta emitters because the dense ionization they produce causes irreparable DNA damage regardless of oxygenation status.

Clinical Indication

Ra-223 is indicated for symptomatic bone metastases from castration-resistant prostate cancer in patients with no known visceral metastatic disease (lymph nodes up to 3 cm are permitted). Patients must be on androgen deprivation therapy or have undergone bilateral orchiectomy and must have at least 2 bone metastases on bone scan.

Patient Selection

Inclusion Criteria (ALSYMPCA-Based)

Eligible patients have mCRPC with symptomatic bone metastases and at least 2 bone metastases on bone scintigraphy. There must be no visceral metastases to the lung, liver, or brain. Patients must have received prior docetaxel or be unfit or unwilling for docetaxel. ECOG performance status must be 0 to 2.

Laboratory Requirements

Required laboratory values include an absolute neutrophil count of 1,500/mm3 or greater, platelet count of 100,000/mm3 or greater, hemoglobin of 10 g/dL or greater, and adequate renal and hepatic function.

Contraindications

Contraindications include any visceral metastases, concurrent chemotherapy (specifically the combination of abiraterone plus prednisone, which showed harm in the ERA-223 trial), severe bone marrow suppression, fecal incontinence (which raises radiation safety concerns since Ra-223 is excreted via the GI tract), and imminent spinal cord compression or pathologic fracture requiring intervention.

Treatment Protocol

Dosing

The dose is 55 kBq/kg (1.49 microCi/kg) body weight per injection, administered for 6 injections at 4-week intervals. Each dose is given as a slow intravenous bolus over 1 minute. No special patient preparation is required.

Monitoring Schedule

A complete blood count is obtained before each cycle and must meet minimum thresholds. The dose is delayed if the absolute neutrophil count falls below 1,000, platelets fall below 50,000, or other significant toxicity develops. Alkaline phosphatase (ALP) and PSA are monitored for response assessment. A bone scan at baseline and post-treatment evaluates response.

Efficacy

ALSYMPCA Trial Results

The ALSYMPCA trial was a randomized phase III study comparing Ra-223 plus best standard of care to placebo plus best standard of care. Median overall survival was 14.9 months versus 11.3 months, with a hazard ratio of 0.70 and a p-value of less than 0.001. Time to first symptomatic skeletal event was 15.6 months versus 9.8 months. Alkaline phosphatase declined by 30% or more in 87% versus 23% of patients. Significant improvement in quality of life, pain, and functional scores was observed. The survival benefit was consistent across all subgroups.

Response Assessment

Alkaline phosphatase decline is the most useful biochemical marker for assessing response. PSA response is variable and less reliable with Ra-223 therapy. Bone scan may show an initial flare phenomenon before improvement. CT or MRI is obtained for soft tissue assessment if clinically indicated.

Toxicity

Hematologic Effects

Thrombocytopenia is the most significant hematologic toxicity, with a nadir typically at 2 to 3 weeks after injection. Anemia is common but usually mild. Neutropenia is less common. Overall, hematologic toxicity is generally mild and reversible. Patients with extensive bone marrow involvement are at higher risk.

Gastrointestinal Effects

Mild nausea occurs in approximately 30% of patients. Diarrhea occurs in approximately 25%, reflecting the fact that Ra-223 is excreted via the gastrointestinal tract. Vomiting is less common.

Bone Effects

A bone pain flare may occur early in treatment and suggests response. Pathologic fractures should be monitored for clinically. Long-term concern for osteonecrosis exists but has not been commonly observed.

ERA-223 Lesson

The ERA-223 trial demonstrated that the combination of Ra-223 with abiraterone plus prednisone resulted in increased fractures and possible harm. This combination is now contraindicated. Concurrent use of bone-protective agents such as denosumab or zoledronic acid is recommended.

Radiation Safety

Unique Considerations for Alpha Emitters

Ra-223 is primarily excreted via the fecal route through the gastrointestinal tract. External exposure is low due to minimal gamma emission. Patients can typically be treated as outpatients. Standard precautions for bodily fluids include proper toilet hygiene and handwashing. Staff exposure is minimal with standard precautions, and there are no specific patient release criteria issues.

Comparison with Other Bone-Targeted Therapies

Sm-153 EDTMP (Quadramet) is a beta emitter used for palliation only with no survival benefit. Sr-89 (Metastron) is also a beta emitter with palliative use only and no survival benefit. Ra-223 is the only bone-targeted agent with a proven survival benefit. Lu-177 PSMA targets PSMA rather than bone specifically and addresses soft tissue and visceral disease as well. Ra-223 and Lu-177 PSMA address different patient populations: Ra-223 is for bone-predominant disease without visceral metastases, while Lu-177 PSMA can be used in patients with both bone and soft tissue disease.

Clinical Pearls

Ra-223 is the only alpha-emitting radiopharmaceutical with a proven overall survival benefit in oncology and is strictly indicated for bone-predominant mCRPC without visceral metastases.

The combination of Ra-223 with abiraterone plus prednisone is contraindicated based on ERA-223 data showing increased fractures. Bone-protective agents should be co-administered with Ra-223 therapy.

Thrombocytopenia is the dose-limiting hematologic toxicity. CBC must be checked before each cycle, and treatment should be delayed or discontinued if platelets fall below 50,000/mm3.

References

1. Parker C, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer (ALSYMPCA). New England Journal of Medicine. 2013;369(3):213-223.
2. Smith M, et al. Addition of Radium-223 to Abiraterone Acetate and Prednisone (ERA-223). Lancet Oncology. 2019;20(3):408-419.
3. Defined SNMMI Procedure Standard for Ra-223 Therapy. Journal of Nuclear Medicine. 2020;61(5):e1-e10.
4. Defined Clinical Practice Guidelines for Ra-223 in mCRPC. European Urology. 2021;79(2):243-257.

Read this lecture as Markdown